Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections

Core Insights - Basilea Pharmaceutica Ltd has entered into a collaboration with Prokaryotics Inc. to develop a first-in-class broad-spectrum antifungal targeting severe invasive infections [1][2] - The partnership aims to address the unmet medical needs for antifungal treatments against pathogens like Candida and Aspergillus, which are critical for immunocompromised patients [2][4][5] - Basilea will handle clinical development and commercialization, while Prokaryotics will receive milestone payments and royalties based on sales [3] Company Overview - Basilea is a commercial-stage biopharmaceutical company focused on developing innovative drugs for severe bacterial and fungal infections, with existing products like Cresemba and Zevtera [8] - The company has a robust anti-infective R&D pipeline, indicating a strong commitment to addressing medical needs in this area [3][8] - Prokaryotics specializes in discovering novel anti-infective drugs, particularly targeting multidrug-resistant infections, and emphasizes the need for new antifungal agents with unique mechanisms of action [6]